MYD88 and diffuse large B-cell lymphoma: Patients with ABC-DLBCL usually have a worse prognosis than those with GCB-DLBCL, and oncogenic mutations in NF-κB signaling proteins, such as in the CD79B, CARMA1, MYD88, and A20 genes, are associated with ABC-DLBCL.